| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.17 | 9e-05 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0003 |
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0004 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0004 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | -0.18 | 0.0006 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.18 | 0.0007 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.002 |